Product Name:2,6-dichloro-9H-purine

IUPAC Name:2,6-dichloro-9H-purine

Molecular Formula:C5H2Cl2N4
Catalog Number:CM105234
Molecular Weight:189

Packing Unit Available Stock Price($) Quantity
CM105234-100g in stock ĜĜǭ
CM105234-500g in stock ţţƩ

For R&D use only.

Inquiry Form


Product Details

CAS NO:5451-40-1
Molecular Formula:C5H2Cl2N4
Melting Point:-
Smiles Code:ClC1=NC(Cl)=C2N=CNC2=N1
Catalog Number:CM105234
Molecular Weight:189
Boiling Point:405.4°C at 760 mmHg
MDL No:MFCD00077725
Storage:Keep in a tight container and store at ambient temperature

Category Infos

Purines are heterocyclic aromatic compounds composed of linked pyrimidine and imidazole rings. In mammals, purines are most commonly expressed in DNA and RNA (including the purines adenine and guanine), as well as single-molecule nucleotides (adenosine triphosphate (ATP), adenosine diphosphate (ADP), adenosine monophosphate (AMP), cyclic AMP, and to a lesser extent guanosine triphosphate (GTP) and cyclic guanosine monophosphate (cGMP). Purines are also key elements of the following energy metabolism molecules: reduced nicotinamide adenine dinucleotide, nicotinamide adenine dinucleotide phosphate (NADPH), and coenzyme Q. Purines can also act as direct neurotransmitters; for example, adenosine may interact with receptors to modulate cardiovascular and central nervous system (CNS) function.
purine wholesale
Find trusted purine wholesaler. Any requirements and problems can ask us at any time.
Nucleosides and Nucleotides
Nucleosides consist of a nucleotide and a five-carbon sugar, and a nucleotide consists of a nucleotide, a five-carbon sugar, and one or more phosphate groups.
nucleoside manufacturer
As a professional nucleoside manufacturer, we can guarantee product quality and delivery time.our company has been committed to supply personalized product solutions to customers,pls consult us.

Column Infos

Namodenoson is a small orally bioavailable drug that binds with high affinity and selectivity to the A3 adenosine receptor (A3AR). Namodenoson was evaluated in Phase II trials for two indications, as a second line treatment for hepatocellular carcinoma, and as a treatment for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).
Namodenoson granted Orphan Drug and Fast track status from the FDA. A3AR is highly expressed in diseased cells whereas low expression is found in normal cells. This differential effect accounts for the excellent safety profile of the drug.